1. Home
  2. OMER vs MTW Comparison

OMER vs MTW Comparison

Compare OMER & MTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • MTW
  • Stock Information
  • Founded
  • OMER 1994
  • MTW 1902
  • Country
  • OMER United States
  • MTW United States
  • Employees
  • OMER N/A
  • MTW N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • MTW Construction/Ag Equipment/Trucks
  • Sector
  • OMER Health Care
  • MTW Industrials
  • Exchange
  • OMER Nasdaq
  • MTW Nasdaq
  • Market Cap
  • OMER 304.9M
  • MTW 358.5M
  • IPO Year
  • OMER 2009
  • MTW N/A
  • Fundamental
  • Price
  • OMER $4.06
  • MTW $10.01
  • Analyst Decision
  • OMER Strong Buy
  • MTW Hold
  • Analyst Count
  • OMER 5
  • MTW 4
  • Target Price
  • OMER $18.00
  • MTW $11.00
  • AVG Volume (30 Days)
  • OMER 730.2K
  • MTW 293.6K
  • Earning Date
  • OMER 11-12-2025
  • MTW 10-29-2025
  • Dividend Yield
  • OMER N/A
  • MTW N/A
  • EPS Growth
  • OMER N/A
  • MTW 436.41
  • EPS
  • OMER N/A
  • MTW 1.26
  • Revenue
  • OMER N/A
  • MTW $2,131,200,000.00
  • Revenue This Year
  • OMER N/A
  • MTW N/A
  • Revenue Next Year
  • OMER N/A
  • MTW $4.66
  • P/E Ratio
  • OMER N/A
  • MTW $7.98
  • Revenue Growth
  • OMER N/A
  • MTW N/A
  • 52 Week Low
  • OMER $2.95
  • MTW $7.06
  • 52 Week High
  • OMER $13.60
  • MTW $13.62
  • Technical
  • Relative Strength Index (RSI)
  • OMER 46.53
  • MTW 42.54
  • Support Level
  • OMER $4.07
  • MTW $9.66
  • Resistance Level
  • OMER $4.20
  • MTW $10.46
  • Average True Range (ATR)
  • OMER 0.17
  • MTW 0.31
  • MACD
  • OMER -0.04
  • MTW 0.09
  • Stochastic Oscillator
  • OMER 24.49
  • MTW 43.13

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About MTW Manitowoc Company Inc. (The)

Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.

Share on Social Networks: